Affordable Growth. Analyze the stocks which are showing good growth, decent profitability and health and are not overvalued from a fundamental perspective.
Taking everything into account, HALO scores 8 out of 10 in our fundamental rating. HALO was compared to 563 industry peers in the Biotechnology industry. HALO has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. HALO is growing strongly while it also seems undervalued. This is an interesting combination This makes HALO very considerable for value and growth and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 21.52% | ||
ROE | 122.06% | ||
ROIC | 23% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 54.32% | ||
PM (TTM) | 43.74% | ||
GM | 84.3% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 4.14 | ||
Debt/FCF | 3.21 | ||
Altman-Z | 5.23 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 7.8 | ||
Quick Ratio | 6.78 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 14.89 | ||
Fwd PE | 9.94 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 17.86 | ||
EV/EBITDA | 14.37 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |